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Abstract: Electroconvulsive therapy (ECT) has demonstrated to be highly effective and safe, 
even life saving for many psychiatric disorders such as major depression, bipolar disorder 
and schizophrenia. Most patients who require ECT are also on concurrent pharmacotherapy. 
As such, the objective of this article is to provide a review of the most recent literature focus-
ing on the medications used during an ECT procedure and on the effects of concurrent psy-
chiatric and non-psychiatric medications on the effectiveness and safety of ECT. The review 
also attempts to summarize the recommendations derived from existing documents to guide 
pharmacotherapy decisions for patients undergoing ECT. For this purpose, using electronic 
databases, an extensive search of the current literature was made using ECT and medications 
or drug classes as keywords.
Keywords: ECT, medications, drug interactions
Introduction
Several evidence-based documents on the use of electroconvulsive therapy (ECT) 
indicate that it is a safe and effective treatment for a variety of psychiatric disorders.1–3 
Although major depression refractory to antidepressant medications is the primary 
indication for ECT, there is also significant evidence to support its use in other 
psychiatric disorders such as catatonia, psychotic depression, mania, bipolar disorder 
and schizophrenia.1–3
The goal of ECT is to produce a controlled and monitored seizure lasting from 
30 to 90 seconds in duration to be considered therapeutic.1,4–6 Although the exact mecha-
nism of ECT is unknown, the induced seizure affects nearly every neurotransmitter 
system, including β-adrenergic, serotonin, muscarinic, cholinergic, and dopaminergic 
systems.6,7 Brain-derived neurotrophic factor may also play a role in the efficacy of 
ECT.8 There are no absolute contraindications to ECT; nevertheless, ECT can induce 
side effects and may be physically risky for certain individuals. As such, all patients 
must be assessed prior to ECT for the presence of conditions such as cardiovascular 
disease, space-occupying intracranial lesion with the evidence of elevated intracra-
nial pressure, recent cerebral hemorrhage or stroke, bleeding or otherwise unstable 
vascular aneurysm, and severe pulmonary disease, as all of these can be associated 
with increased risk of complications from the general anesthesia and induction of 
seizure activity.1 ECT is considered safe with a mortality of ~1/10,000 patients or 
1/80,000 treatments.6 Most patients report some adverse cognitive effects during and 
after a course of ECT, such as postictal confusion state (the result of both anesthesia 
and the seizure), anterograde amnesia (decreased ability to retain newly acquired 
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information), and retrograde amnesia (forgetting recent 
memories).9 However, objective tests indicate that cognitive 
abnormalities caused by ECT are generally short lived. Acute 
confusional states typically resolve 10 to 30 minutes after 
the procedure, whereas anterograde amnesia resolves within 
2 weeks after completing the course. Retrograde amnesia 
recovers more slowly than anterograde amnesia.10 Permanent 
memory loss is rare but can occur.9,11 Other adverse effects 
include myalgias, headache, nausea, drowsiness, and mus-
culoskeletal weakness.1,4–7
Several parameters have the potential to influence the 
induction of a well-organized seizure, which is critical for 
ECT efficacy, such as electric stimuli, seizure threshold, and 
medications, including those used during the ECT procedure 
itself, as well as those regularly used to treat the individual’s 
concomitant psychiatric or medical conditions.12 As such, 
assessing all concurrent medications and monitoring for the 
potential effects of these medications before, during, and 
after the ECT procedure are recommended.1–3,6,7 This article 
aims to review all the different classes of medications that 
may be used in patients undergoing ECT and their influence 
on ECT outcomes. Most of the available guidelines describ-
ing medications used in ECT are a decade old, and thus, an 
update on this topic is warranted.
A review of the literature was undertaken using Med-
line (OvidSP), PubMed Central, and Google Scholar using 
the keywords “electroconvulsive therapy”, “drug(s)”, 
“medication(s)”, and “drug/medication interactions”. Only 
studies with human subjects, reports written in the English 
language and published after January 1, 2000, were included. 
Additional references were identified from the bibliogra-
phies of published review articles regardless of the date 
of publication and from ECT guidelines.1–3 In addition, 
using the same electronic databases, separate searches were 
undertaken using ECT and various drugs or drug classes as 
keywords.
The findings have been summarized as 1) medications that 
are used during the ECT procedure and 2) interactions 
between regularly prescribed medications and medica-
tions used during the ECT procedure itself. Management 
strategies for these medication interactions have also been 
extracted from the retrieved articles whenever available to 
help clinicians in making decisions about which medications 
to taper or stop before the procedure, which medications can 
safely be given just before the procedure, and which can be 
continued during the course of ECT (or held until after each 
treatment).
Medications during the ECT 
procedure
Table 1 lists common medications that patients may receive 
during an ECT procedure. These include anesthetic induction 
agents, anticholinergic agents, muscle relaxants, antihyper-
tensives, and narcotics.
Anesthetic agents and muscle relaxants are used to induce 
a state of insensibility and to decrease the likelihood of bone 
and soft tissue injury.1 Due to the brief nature of ECT, an ideal 
anesthetic agent should rapidly induce hypnosis and allow for 
rapid emergence from anesthesia without significantly short-
ening seizure activity or causing hemodynamic instability.13,14 
Among the barbiturates, methohexital and thiopental, which 
have minimal anticonvulsant properties compared with other 
barbiturates, were considered as gold standard as ECT anes-
thetic induction agents, but due to recent worldwide shortages 
of these agents, other drugs such as propofol, etomidate and 
ketamine have become more widely used.15–21
The advantages of propofol over methohexital include 
a quicker and smoother emergence from anesthesia and a 
somewhat more favorable hemodynamic profile.14–17 Dis-
advantages are its much greater anticonvulsant effect and 
higher cost. Etomidate is an alternative particularly in patients 
who have seizures of short duration or hard to elicit.14,17,20 
Ketamine has shown to be slightly proconvulsant and has 
intrinsic antidepressant properties. Disadvantages include 
hypertension and occasional transient dissociative symptoms 
on wake up.17,19,21 A recent systematic review concluded that 
robust evidence to recommend a particular induction agent 
for ECT is lacking and indicated that anesthetic agents should 
Table 1 Medications during the ecT procedure
Anesthetic induction  
agents
Methohexital
Thiopental
Propofol
etomidate
Ketamine
Neuromuscular  
blocking agents
succinylcholine (suxamethonium)
rocuronium
Atracurium
Mivacurium
Antihypertensives β-blockers (atenolol, esmolol, and labetalol)
calcium channel blockers (nifedipine and 
nicardipine)
Anticholinergic  
agents
Glycopyrrolate
Atropine
Narcotics Fentanyl
remifentanyl
Alfentanyl
Abbreviation: ecT, electroconvulsive therapy.
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be chosen on the basis of adverse effect profile, emergence, 
and how these medications affect seizure duration.18 Opioids, 
such as remifentanil and alfentanil, combined with anesthetic 
agents have been used to increase the seizure duration by 
an induction agent dose-sparing effect.17,22–24 Caffeine, 
in the form of caffeine sodium benzoate intravenous injection 
250–1,000 mg, and other methylxanthines have also been 
administered prior to ECT to increase the seizure duration 
but do not appear to reduce seizure threshold.24 However, 
because the potential cardiac and other complications of caf-
feine use are known, this augmenting strategy is not generally 
recommended, especially in the elderly.24,25 Muscle relaxation 
during the application of the stimulus, as well as for the 
duration of the motor portion of the seizure, prevents mus-
culoskeletal injury; this is especially important if the patient 
has osteoporosis or a history of spinal injury.1,6,7 Because of 
the short duration of ECT, succinylcholine (also known as 
suxamethonium) is the drug of choice for neuromuscular 
blockade.1,17,26 Succinylcholine is a depolarizing neuromus-
cular blocker with an ultrashort duration of action, slightly 
less than that of the anesthetic agent. The duration of muscle 
paralysis is, thus, very brief, and spontaneous respirations 
return shortly after the seizure ends. In patients in whom its 
use is contraindicated, rocuronium or other nondepolarizing 
agents are alternatives.1,26
During ECT, significant changes in autonomic function 
can occur. Initially a parasympathetic surge can result in 
significant bradycardia, hypotension, and, in some cases, 
brief asystole.1,6 Patients already on β-blockers may be at 
risk of bradycardia if stimulation is given but a seizure is 
not induced.4,7 To counteract the parasympathetic effect, 
anticholinergic medications (eg, glycopyrrolate and atro-
pine) may be given, although this is not routinely required. 
Glycopyrrolate is preferred over atropine since it does not 
cross the blood–brain barrier, which reduces unwanted cogni-
tive effects after ECT.6
Following stimulus termination, the resulting seizure is 
accompanied by a profound sympathetic surge, typically 
associated with tachycardia and hypertension.1,27 Deleteri-
ous sympathetic effects may be controlled with β-blockers 
either pre- (atenolol) or intraprocedurally (labetalol and 
esmolol).13,17 There is controversy, however, regarding 
whether labetalol and esmolol reduce seizure duration.28 
Sublingual nifedipine and intravenous nicardipine have been 
used (although tachycardia can occur), as has diltiazem, 
although it also may reduce seizure duration.27 Preopera-
tive α-2 agonists, such as dexmedetomidine, also blunt the 
hyperdynamic response as does glyceryl trinitrate, which 
should be considered in patients at high risk of myocardial 
ischemia.17,27,28
Interactions between regularly 
prescribed medications and ECT
The majority of patients requiring ECT are likely to be 
receiving concurrent regularly prescribed medications 
for treating psychiatric, medical, and comorbid condi-
tions. Therefore, not surprisingly, drug interactions can 
occur between psychotropic agents, drugs prescribed for 
chronic medical conditions, anesthesia-inducing agents, 
and other medications used for the ECT procedure itself. 
These drug interactions can be classified into the following 
categories: 1) interactions with medications used during 
the ECT procedure, 2) interactions that affect the efficacy 
of ECT (ie, suppressing seizure activity), and 3) interac-
tions that can increase the risks associated with ECT (eg, 
increase risk of complications, such as prolonged seizures 
and cardiotoxicity).
In general, medications that raise seizure threshold or 
impede seizure propagation (interfere with induction or 
spread of a robust seizure) should be avoided if possible, 
or the dose decreased (eg, anticonvulsants and benzodi-
azepines). Cardiac medications, antihypertensives, and 
antigastric medications can typically be continued. Table 2 
provides a summary of the most often reported drug interac-
tions based on the major classes of commonly used medica-
tions by patients undergoing ECT. For each specific drug 
interaction, the possible undesired effect and how it can be 
managed are also included for easy reference. There are no 
studies exploring the effects of herbal medicines on ECT; 
however, several direct and indirect mechanisms whereby 
such use may impact the ECT procedure are also summarized 
in Table 2.
Conclusion
Despite the vast potential for drug interactions in patients 
receiving ECT, available evidence on those interactions 
that are clinically significant is scarce, and it is almost 
exclusively retrospective in nature, or derived from case 
reports or case series. A summary of the existing evidence 
as presented in this article can inform clinicians on the 
potential and documented consequences of these interac-
tions, and assist them weighing the risks and benefits before 
making decisions on the concurrent use of medications in 
patients receiving ECT.
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Table 2 Drug interactions reported in patients undergoing ecT
Class Evidence Possible undesired effect Management strategies
Anticonvulsants/mood stabilizers
Lithium6,29–31 •	 Combination has a significant risk 
of delirium, prolonged seizures, 
toxic lithium levels, and prolonged 
neuromuscular blockade
•	 combination not an absolute 
contraindication. in certain 
emergencies where the benefits 
clearly outweigh the risks, 
combined therapy could be 
considered
•	 case reports in elderly patients 
indicate that only 24 hours of 
holding lithium therapy might 
result in a lithium level sufficient 
to contribute to delirium 
after ecT
•	 Delirium, postictal confusion (the 
elderly may be at increased risk)
•	 Prolonged seizure duration
•	 increased lithium levels
•	 Prolonged action of neuromuscular 
blocking agents (eg, succinylcholine)
•	 Potential serotonin syndrome
•	 Avoid combination if possible
•	 if lithium cannot be discontinued, 
give at a dose to maintain a blood 
level in the lowest therapeutic 
range and/or hold day before ecT
•	 if patient is already taking lithium 
without clear benefit, stop lithium 
before ecT. A washout period 
is unnecessary unless high blood 
level is present
•	 if lithium has provided clear 
benefit, lithium can be continued 
during index ecT, with close 
monitoring for unwanted adverse 
effects at the lowest possible 
therapeutic level
•	 Alternatively, substitute lithium 
for another mood stabilizer (eg, 
atypical antipsychotic) to provide 
protection against mania while 
ecT is being given for depression
•	 Nondepolarizing neuromuscular 
blockers should be administered 
in incremental and reduced doses 
and titrated to the degree of block 
required
vPA14,32–34 •	 Case reports of difficulty in 
eliciting seizures with patients 
on vPA
•	 Possible drug–drug interaction 
competing for protein binding, 
which can elevate vPA levels
•	 Decrease in the propofol dose 
required to induce anesthesia 
during ecT in the presence 
of vPA
•	 Seizure inhibition or difficulty in 
eliciting adequate seizures during ecT
•	 Theoretically, the anticonvulsant 
activity of vPA may interact with the 
efficacy of ECT
•	 Dose reduction or withholding 
doses (eg, the morning of, or the 
evening or morning prior to the 
ecT procedure)
•	 changing the anesthetic regimen 
(addition of remifentanyl to a 
lower dose of methohexital, 
or etomidate instead of 
methohexital), to produce 
adequate seizures
cBZ14,32,33 •	 case reports show mixed results. 
some indicate no negative effect 
of cBZ on ecT, and others 
report difficulty in eliciting 
seizures
•	 cBZ–ecT group compared to 
control group had a shorter 
duration of seizures and a higher 
stimulus dose when unilateral 
treatments were used
•	 Development of moderately 
severe postictal confusion has also 
been reported
•	 cBZ may prolong the action 
of succinylcholine (few clinical 
implications)
•	 Long-term cBZ demonstrated 
resistance to nondepolarizing 
neuromuscular blockers (except 
mivacurium)
•	 seizure inhibition
•	 Accelerated recovery and need for 
increased doses to achieve complete 
neuromuscular block (induce a 
mild upregulation of neuromuscular 
acetylcholine)
•	 Dose reduction or withholding 
doses (eg, the morning of, or the 
evening or morning prior to the 
ecT procedure)
•	 Neuromuscular blockade: if 
suxamethonium is contraindicated, 
mivacurium seems to be the 
preferred neuromuscular blocker 
in patients receiving cBZ therapy
(Continued)
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Table 2 (Continued)
Class Evidence Possible undesired effect Management strategies
LTG14,32,34,35 •	 case reports/series show minimal 
or no influence on seizures and/or 
seizure duration
•	 interaction with halothane; 
reducing effect of LTG on 
glutamate release, either at the 
receptor or via effects at the 
inactivated sodium channel
•	 ecT attenuates the inhibitory 
dose-dependent effects of LTG 
on synaptic transmission at a low 
frequency. Clinical significance 
remains unknown
•	 Theoretically, seizure inhibition •	 None have been recommended
Others: 
gabapentin14,32,34 
and topiramate36
•	 No complications were found in 
two case reports using gabapentin
•	 No interactions have as yet been 
reported between gabapentin or 
topiramate and the anesthetics 
used for ecT
•	 The use of topiramate for post-
ecT headaches did not result in 
adverse ecT outcomes
•	 Theoretically, seizure inhibition •	 None have been recommended
Antidepressants
MAOi4,14,37–39 •	 No evidence of an interaction 
between ecT and MAOi use
•	 A prospective study looked at 
the risks associated with the 
combination of MAOis and ecT, 
no differences between the study 
and control groups were reported
•	 Ketamine should be avoided as it 
causes sympathetic stimulation. 
Propofol and etomidate can be 
used safely with MAOis
•	 Theoretically, risk of hypertensive 
crisis if combined with indirect acting 
sympathomimetics
•	 Usual recommendation for the 
combination of MAOi with other 
medications should be provided to 
avoid hypertensive crises
•	 if the MAOi has not been 
effective, a cautious approach 
when discontinuing the MAOi 
before ecT is recommended. 
There is no need for a washout 
period before starting ecT
•	 if the medication has been helpful, 
the MAOi can be continued. 
Alternatively, patients could be 
switched to a reversible MAOi 
(eg, moclobemide) as it carries a 
decreased risk
TcA4,6,14,39,40 •	 retrospective review of the 
literature found that the use 
of TcAs in combination with 
ecT was associated with better 
outcomes and shorter total 
seizure time than with ecT alone
•	 No differences were found in 
the measures of confusion and 
cardiac adverse effects, and there 
was even a trend toward fewer 
adverse effects in the groups 
receiving the ecT and TcA 
combination
•	 Theoretically, reduced seizure 
threshold and an increased risk of 
cardiotoxicity
•	 chronic therapy with TcAs depletes 
cardiac catecholamines, potentiating 
the cardiac depressant effects of 
anesthetic agents
•	 The TcA dose should be 
decreased if possible to minimize 
the likelihood of an exaggerated 
hypertensive response during ecT
•	 Abrupt withdrawal of TcAs 
should be avoided because of 
the risk of mainly cholinergic 
symptoms
•	 Best avoid TcA use in the 
elderly and in those with cardiac 
conditions
Others1,4,14,39–45 •	 Minimal effect on ecT-related 
seizure duration has been 
reported with ssris, sNris, or 
trazodone
•	 Theoretically, reduced seizure 
threshold with ssris and sNris
•	 seizure length may increase when 
ecT is administered during bupropion 
treatment
•	 some clinicians recommend 
bupropion discontinuation or dose 
reduction prior to ecT
(Continued)
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Table 2 (Continued)
Class Evidence Possible undesired effect Management strategies
•	 Possibility of increased risk of 
asystole with venlafaxine (sNri) 
at doses .300 mg/d
•	 status epilepticus has been 
reported with concomitant use of 
bupropion during ecT
•	 serotonin syndrome has been 
reported with paroxetine and 
fluoxetine
•	 Pharmacokinetic interactions with 
some ssris and anesthetic agents
•	 if ssris are discontinued, clinicians 
should be aware that withdrawal 
may cause symptoms similar 
to the side effects of ecT (eg, 
headache, myalgia, nausea, and 
fatigue)
•	 it is necessary to pay attention to 
the rare side effect of serotonin 
syndrome by ecT in combination 
with ssris
Anxiolytics
BZD6,14,39 •	 The impact of BZDs on seizure 
adequacy may be low if the BZD 
has been routinely used
•	 can produce additive sedative 
effects during the anesthetic 
induction phase
•	 increased seizure threshold, 
decreased seizure duration, and 
decreased potential efficacy of ECT
•	 Possibly increased cognitive side 
effects when given with ecT
•	 if possible, stop BZD before ecT. 
Many BZDs are long acting and 
may need to be discontinued 
some days before ecT
•	 if the BZD cannot be 
discontinued, the use of higher 
stimulus or using flumazenil 
just before ecT to temporarily 
reverse effects of the BZD has 
been suggested
•	 The dose of thiopental or 
propofol used for induction of 
anesthesia should be titrated to 
the desired effect
Antipsychotics
FGA1,14,39,46 •	 The combination of FGAs, 
particularly phenothiazines (eg, 
chlorpromazine) and ecT has 
been reported to cause prolonged 
seizures
•	 Theoretically, FGAs reduce seizure 
threshold
•	 None have been recommended
•	 Their antiadrenergic and 
anticholinergic effects are 
unpredictable, and caution in the 
use of drugs with similar effects 
during anesthesia should be 
exercised
sGA14,39,46 •	 Some data suggest beneficial 
and additive efficacy when in 
combination, particularly with 
clozapine
•	 clozapine is known to decrease 
the seizure threshold in a dose-
dependent manner (usually at doses 
.600 mg/d)
•	 None have been recommended
•	 For patients on clozapine, a dose 
reduction prior to ecT may be 
considered
CNS stimulants
Methylphenidate14 •	 Methylphenidate was shown to 
reduce sedation and improve 
respiratory function in patients 
recovering from halothane 
anesthesia
•	 Theoretically, there is an increased 
risk for potentiating seizure activity, 
thereby leading to prolonged 
seizures or a risk for status 
epilepticus
•	 Methylphenidate can also produce 
dysrhythmias and elevate blood 
pressure during anesthesia
•	 None have been recommended
Miscellaneous
cholinesterase 
inhibitors4,47,48
•	 No evidence of adverse incidents 
involving concurrent use with 
ecT
•	 successful use of donepezil 
in treating cognitive deficits 
associated with maintenance ecT 
has been reported
•	 Theoretically, synergistic effects with 
neuromuscular blocking agents. This 
combination also has the potential to 
induce significant bradycardia, cardiac 
arrhythmias, and asystole
•	 caution has been recommended 
particularly with neuromuscular 
blocking agents
Lidocaine1,7,17,49,50 •	 ineffective in ameliorating the 
robust sympathetic response 
associated with ecT
•	 seizure inhibition
•	 Potentially useful for reducing 
tachycardia in high-risk patients and 
reducing the severity of propofol 
injection pain
•	 recommended to be used only 
in life threatening situations 
to control heart rate, when 
β-blockers are not available or are 
contraindicated
(Continued)
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Table 2 (Continued)
Class Evidence Possible undesired effect Management strategies
•	 Pretreatment with lidocaine is 
associated with decreased seizure 
duration and a higher likelihood 
of patients requiring multiple 
applications of electric current 
during a single ecT session to 
achieve a therapeutic seizure
Theophylline4,6,14 •	 reports of status epilepticus after 
ecT
•	 High levels of theophylline during 
ecT associated with status 
epilepticus
•	 can increase seizure duration and 
increase risk of status epilepticus
•	 if possible, discontinue 
theophylline by tapering the 
dose. continue with a regimen 
of bronchodilators and inhaled 
glucocorticoids
•	 Alternatively, decrease dose to 
the lowest therapeutic drug level 
and monitor levels closely
•	 Provide standard treatment during 
an asthma exacerbation (inhaled 
β-agonists and, if necessary, 
glucocorticoids, before proceeding 
with ecT)
Antigastric agents 
(eg, antacids and 
proton pump 
inhibitors)6,51
•	 No evidence of adverse incidents 
involving concurrent use with 
ecT
•	 continue as patients with GerD 
may have worsened symptoms 
undergoing ecT due to vagal 
stimulation
Diabetic 
agents (eg, oral 
hypoglycemics 
and insulin)7,51
•	 individual ecT treatments raise 
blood glucose levels in patients 
with diabetes to the same degree 
as in patients without diabetes
•	 can cause hypoglycemia •	 Measure blood glucose levels 
before and after ecT treatment. 
Give half the usual amount of 
long-acting insulin in the morning 
of the procedure
•	 Withhold oral agents until patient 
can eat. Provide short-acting 
insulin to treat elevations in blood 
glucose level
Warfarin51–53 •	 A retrospective case review 
found that over one-third of the 
patients iNrs during ecT were 
subtherapeutic
•	 However, ecT appears to be safe 
in patients who require long-term 
anticoagulation
•	 The potential for methohexital to 
increase the metabolism of warfarin, 
decrease the iNr, and possibly affect 
warfarin’s efficacy exists
•	 continue anticoagulation to 
maintain an iNr of up to 3.5, 
unless there is an increased risk 
of intracranial hemorrhage (eg, 
intracranial mass or aneurysm)
Herbals54 Mechanism of action and potential effect on ECT Management strategies
Gingko biloba •	 GABA agonist: potentiates cNs depressant effects of barbiturates and BZDs 
and may increase ecT seizure threshold
•	 inhibit platelet activating factor: increase risk of cerebral hemorrhage
•	 May contain convulsive agent: lower ecT seizure threshold
•	 cerebral arterial vasodilation: increased intracranial pressure
•	 induce cYP3A4: increase metabolism of barbiturates and BZDs
•	 For all herbal medicines: assess 
its potential impact on the 
procedure, weigh benefits, and 
risk
•	 similar considerations when 
assessing conventional 
pharmacotherapy
Ginseng •	 cNs depressant: potentiates cNs depressant effects of barbiturates and BZDs 
and may increase ecT seizure threshold
•	 cNs stimulant: may increase anesthetic requirement and decrease ecT seizure 
threshold
•	 Facilitates acetylcholine release: parasympathetically mediated bradycardia
st Johns Wort •	 GABA agonist: potentiates cNs depressant effects of barbiturates and BZDs 
and may increase ecT seizure threshold
•	 reduces cholinesterase levels: potentiates neuromuscular blockade effect 
(eg, succinylcholine)
•	 inhibits MAO and cOMT: hypertension or cardiovascular collapse
(Continued)
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Table 2 (Continued)
Herbals54 Mechanism of action and potential effect on ECT Management
valerian •	 cNs depressant, GABA agonist, inhibits GABA uptake and metabolism: potentiates 
cNs effects of barbiturates and BZDs and may increase ecT seizure threshold
Kava kava •	 cNs depressant, GABA agonist: potentiates cNs effects of barbiturates and 
BZDs and may increase ecT seizure threshold
Abbreviations: BZD, benzodiazepine; CBZ, carbamazepine; ECT, electroconvulsive therapy; FGA, first-generation antipsychotics; LTG, lamotrigine; MAOI, monoamine 
oxidase inhibitor; sGA, second-generation antipsychotics; sNris, serotonin norepinephrine reuptake inhibitors; ssris, serotonin reuptake inhibitors; TcA, tricyclic 
antidepressant; VPA, valporic acid; CNS, Central Nervous System; GERD, Gastroesophageal Reflux Disease; INR, International Normalization Ratio; COMT, Catecholl-O-
Amine Transferase; GABA, Gamma Amino-Butiric Acid.
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